Processa Pharmaceuticals (PCSA) CFO adds 1,984 shares in Form 4 buy

Rhea-AI Filing Summary

Processa Pharmaceuticals, Inc. Chief Financial Officer Russell Skibsted reported an open-market purchase of the company’s Common Stock. On May 15, he bought 1,984 shares at $2.97 per share, bringing his direct holdings to 8,466 shares.

The filing also notes that share totals were adjusted to correct immaterial errors in a prior Form 4. The corrected price for a purchase on April 30 is stated as $2.71 instead of $2.69, which reduced that earlier purchase by 16 shares.

Insider Trade Summary

Net Buyer: 1,984 shares ($5,892)

Net Buy 1 txn

Insider SKIBSTED RUSSELL

Role Chief Financial Officer

Bought 1,984 shs ($6K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	1,984	$2.97	$6K

Holdings After Transaction: Common Stock — 8,466 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares purchased: 1,984 shares Purchase price: $2.97 per share Post-transaction holdings: 8,466 shares +3 more

6 metrics

Shares purchased 1,984 shares Open-market purchase of Common Stock on May 15

Purchase price $2.97 per share Price paid for 1,984 shares on May 15

Post-transaction holdings 8,466 shares Direct Common Stock owned after the May 15 trade

Corrected April 30 price $2.71 per share Revised price for prior April 30 purchase

Previously reported April 30 price $2.69 per share Original, incorrect price later corrected

April 30 share reduction 16 shares Decrease in April 30 purchase due to correction

Key Terms

open-market purchase, Form 4, immaterial errors

3 terms

open-market purchase financial

"Purchase in open market or private transaction"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

immaterial errors regulatory

"Shares adjusted to correct immaterial errors made on the Form 4"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SKIBSTED RUSSELL

(Last) (First) (Middle)

C/O PROCESSA PHARMACEUTICALS, INC.

601 21ST STREET SUITE 300

(Street)

VERO BEACH FLORIDA 32960

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Processa Pharmaceuticals, Inc. [ PCSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/15/2026		P		1,984	A	$2.97	8,466(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares adjusted to correct immaterial errors made on the Form 4 filed on May 1, 2026. The corrected price per share for the purchase made on April 30, 2026 is $2.71, not $2.69, which reduces the amount purchased on April 30, 2026 by 16 shares.

	/s/ Russell Skibsted by John J. Wolfel, as Attorney-in-Fact	05/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Processa Pharmaceuticals (PCSA) report on this Form 4?

Processa Pharmaceuticals reported that its Chief Financial Officer, Russell Skibsted, made an open-market purchase of Common Stock. He bought 1,984 shares on May 15 at a price of $2.97 per share, increasing his directly held stake in the company.

How many Processa Pharmaceuticals (PCSA) shares does the CFO hold after this transaction?

After the reported transaction, the CFO directly holds 8,466 shares of Processa Pharmaceuticals Common Stock. This figure reflects his position following the May 15 open-market purchase of 1,984 shares at $2.97 per share disclosed in the Form 4 filing.

At what price did the Processa Pharmaceuticals (PCSA) CFO buy shares on May 15?

The CFO bought Processa Pharmaceuticals Common Stock at $2.97 per share on May 15. The Form 4 specifies an open-market purchase of 1,984 shares at this price, with the transaction classified as a direct ownership change in the company’s Common Stock.

What correction to an earlier Processa Pharmaceuticals (PCSA) trade is disclosed in the footnote?

The footnote explains that previously reported figures for an April 30 purchase were corrected. The proper price per share is $2.71 instead of $2.69, which reduces the April 30 purchase amount by 16 shares, and the filing describes these as immaterial errors.

Does this Processa Pharmaceuticals (PCSA) Form 4 involve derivative securities or options?

This Form 4 relates only to Common Stock, with no derivative transactions reported. The summary data show one non-derivative open-market purchase of 1,984 shares and a derivativeSummary section with no remaining derivative positions visible in this particular filing.